Patient Condition
The patient developed mild cognitive impairment in 2022, and his memory declined significantly. Johns Hopkins Hospital assessment showed that the MMSE score was 21 points, and amyloid PET was strongly positive. Early AD was diagnosed.
Treatment Timeline
| Phase | Details | Date |
|---|
| Comprehensive evaluation and staged diagnosis | | |
| Lecanemab low-dose start +Troriluzole combination | | |
| Combination therapy + cognitive rehabilitation enhancement | | |
| Maintenance treatment and functional maintenance | | |
Treatment Outcome
| before | MMSE score 21 points, mild cognitive impairment, and significant decrease in memory |
|---|
| after | MMSE score 25 points (improvement 4 points), cognitive function is stable, and amyloid load is reduced |
|---|
| highlight | Good amyloid clearance and improved cognitive function |
|---|